No Survival Benefit from Adding Cetuximab or Panitumumab to Oxaliplatin-Based Chemotherapy in the First-Line Treatment of Metastatic Colorectal Cancer in KRAS Wild Type Patients: A Meta-Analysis
Figure 7
Funnel plot for publication bias test OS.
The two oblique lines indicate the pseudo 95% confidence limits.